Xanamem proof-of-concept trial demonstrating anti-depressant activity published in the British Journal of PsychiatryOngoing Xanamem (emestedastat) Alzheimer’s disease pivotal trial progresses toward final results in November this year
Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease programXanaMIA randomized, pivotal trial of oral Xanamem 10 mg fully enrolled and remains on track for topline final results in November 2026
Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business updateRandomized phase of XanaMIA pivotal trial of oral Xanamem 10 mg remains on track for topline final results in November 2026
Actinogen provides pivotal Alzheimer’s trial enrolment update and other business newsPhase 2b/3 Alzheimer’s trial enrolment expected to reach 100 this quarter, triggering an interim analysis 6 months later
